Oxodipine

Oxodipine, a dihydropyridine-type calcium antagonist, inhibits KCl-induced aortic contraction in rabbits and reduces cardiac force in less potent rat ventricular test-paper contractions. In rat cultured neonatal ventricular myocytes, Oxodipine reduces L-type Ca currents (I) with an IC50 of 0.24 μM, and against T-type Ca currents (I) with an IC50 of 0.41 μM. Oxodipine causes constipation in mice and gingival hyperplasia in dogs[1][2][3][4][5][6].

90729-41-2

12352005

Calcium Channel

Reference compound

Membrane Transporter/Ion Channel; Neuronal Signaling

Neuroscience-Neuromodulation

Cardiovascular Disease; Others

https://www.medchemexpress.com/oxodipine.html

10 mM in DMSO

CCOC(C1=C(C)NC(C)=C(C(OC)=O)C1C2=CC=CC3=C2OCO3)=O

C19H21NO6

359.37

[1]Nyska A, et al. Gingival hyperplasia in rats induced by oxodipine‐a calcium channel blocker[J]. Journal of Periodontal Research, 1990, 25 (2) : 65-68.|[2]Tamargo J, et al. Effects of oxodipine on 45Ca movements and contractile responses in vascular smooth muscle[J]. British journal of pharmacology, 1989, 97 (2) : 339.|[3]Galán L, et al. Characteristics of Ca2+ channel blockade by oxodipine and elgodipine in rat cardiomyocytes[J]. European journal of pharmacology, 1998, 357 (1) : 93-105.|[4]Egros F, et al. An original intragastric delivery system for oral administration of solid formulations to fully conscious rats: its application to oxodipine studies[J]. European Journal of Drug Metabolism and Pharmacokinetics, 1991: 71-76.|[5]Montastruc P, et al. Effect of oxodipine, a novel dihydropyridine calcium channel blocker, in neurogenic hypertensive dogs[J]. Archives internationales de pharmacodynamie et de thérapie, 1993, 321: 57-62.|[6]Tejerina T, et al. Effects of oxodipine on isolated rabbit aorta and mesenteric resistance vessels[J]. European journal of pharmacology, 1992, 219 (2) : 279-284.

Room temperature

Reference compound1